Partners
Collaborate with Us
At Quotient Therapeutics, we believe the promise of somatic genomics extends far beyond our core areas of focus. We seek to collaborate with partners who share our vision of leveraging these unprecedented insights into disease biology to drive the discovery of potentially breakthrough medicines. Together, we can broaden the impact of somatic genomics and bring its transformative potential to the patients who need it most.
Current Collaborators
In 2024, we announced a collaboration with Pfizer and Flagship’s Pioneering Medicines to discover new targets for cardiovascular disease.
In 2025, we announced a collaboration with GSK and Flagship’s Pioneering Medicines to discover and validate new treatments for chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and metabolic dysfunction-associated steatohepatitis (MASH).
In 2026, we announced a collaboration with Merck to discover novel drug targets in inflammatory bowel disease (IBD).